Edwards Lifescience is a long into earnings .

2019年7月10日

While Pharmaceutical and Biopharma stocks have been taking a beating in 2018/19 medical device makers are on a roll , they are in one of the hottest trends in the market, seemingly bullet proof from they bears. EW is on a perfect trend for 2 years and as earnings approach on the 23rd July it looks like a real good bet to move higher.
Indicators are all setting up bullish just at the right time.
Stock is poised to make a nearterm breakout.
News related selling has subsided and they buyers have flocked back in.


AVERAGE ANALYSTS PRICE TARGET $199
AVERAGE ANALYSTS RECOMMENDATION OVERWEIGHT
P/E RATIO 55
SHORT INTEREST 1.8%



COMPANY PROFILE
Edwards Lifesciences Corp. engages in the patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into three areas: Transcatheter Heart Valves, Surgical Structural Heart and Critical Care. The Transcatheter Heart Valves portfolio includes technologies designed to treat heart valve disease using catheter-based approaches as opposed to open surgical techniques. Its portfolio includes technologies designed for nonsurgical replacement of heart valves. The Surgical Structural Heart portfolio includes tissue heart valves and heart valve repair products for the surgical replacement or repair of a patient's heart valve. The portfolio also includes a diverse line of cardiac surgery systems used during minimally invasive surgical procedures, and cannulae, embolic protection devices and other products used during cardiopulmonary bypass. The Critical Care portfolio products hemodynamic monitoring systems used to measure a patient's heart function and fluid status in surgical and intensive care settings. The company was founded by Miles Lowell Edwards in 1958 and is headquartered in Irvine, CA..